Comparative Pharmacology
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus POLARAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus POLARAMINE.
MYMETHAZINE FORTIS vs POLARAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
50 mg orally every 6 hours as needed for nausea and vomiting.
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine